Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Menu

AeBeZe Labs and Digital Nutrition

AI Biotech/Diagnostics: Other Innovation Patent Forecast®

June 27, 2019

AeBeZe Labs, a digital health startup out of Palo Alto, California, recently launced their first app called Moodrise. AeBeZe Labs is a digital health company that believes instead of asking people to completely ditch their phones, they can use images, video, and audio to improve specific brain chemistry. Having filed their first patent application in April 2018 and three more since October 2018, the company is making a push to secure IP in this space. Their app and patent applications focus on the use of machine learning to provide a curated environment to help its users find relaxation, go through rehabilitation, or reduce emotional distress. The company reports they have developed sound environments with smart speaker compatibility, so it will be interesting to see if they team up with a big industry player such as Amazon (Alexa) or Google (Google Home) in the future.


Relevant Patent Documents

Application US20190182193  

Application US20190147043  

Article Source Link

KCRW


View Patent Forecast®

Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.

AI Biotech/Diagnostics: Other Innovation   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.



301